State legislative trends related to biomarker testing

Area of Science:

• Oncology
• Health Services Research
• Health Policy

Background:

• Comprehensive biomarker testing is essential for selecting targeted therapies and immunotherapies in advanced cancer.
• Clinical practice lags behind guidelines in incorporating biomarker testing.
• Disparities in health insurance coverage create significant access barriers for patients.

Purpose of the Study:

• To examine the challenges and disparities in accessing comprehensive biomarker testing for advanced cancer patients.
• To evaluate the impact of insurance coverage policies and state-level legislation on biomarker testing access.
• To highlight the need for continued advocacy to improve biomarker testing accessibility.

Main Methods:

• Review of current clinical guidelines and insurance coverage policies for comprehensive biomarker testing.
• Analysis of state-level legislative efforts to improve access to biomarker testing.
• Examination of patient-related financial barriers, including out-of-pocket costs and prior authorization requirements.

Main Results:

• Insurance coverage variations and high out-of-pocket costs limit access to recommended biomarker testing, contributing to health disparities.
• Prior authorization processes can cause administrative burdens and treatment delays.
• Three states (Illinois, Louisiana, California) have enacted laws to improve access, but these laws vary in scope and impact.

Conclusions:

• Improving access to comprehensive biomarker testing requires addressing insurance coverage limitations and financial burdens.
• State-level legislative actions show promise but need further development and consistent implementation.
• Sustained advocacy by patients, healthcare professionals, and societies is critical to ensure equitable access to biomarker testing for all advanced cancer patients.